PRIM2
ENSG00000146143
Target class
Unclassified protein
Chromosome
6
Approved drugs
4
Clinical candidates (approved and in development)
6
- Approved drugs
- 4
- Clinical candidates (approved and in development)
- 6
- Chemical probe available
- No
- Target name
- PRIM2
- Gene name
- DNA primase subunit 2
- Gene symbol
- PRIM2
- Previous gene symbols
- PRIM2A
- Protein name
- DNA primase large subunit (DNA primase 58 kDa subunit) (p58)
- Gene biotype
- Protein coding
- Gene family
- MicroRNA protein coding host genes
- Target class
- Unclassified protein
- Target type
- Human gene
- Tissues expressed in
- 51
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 27.34
- Tissue specificity (Gini)
- 0.427
- Tissue specificity (tau)
- 0.853
- KEGG gene identifiers
- hsa:5558
- Protein interaction confidence
- 0.877791
- Protein interaction partners
- 67
- R-HSA-113501
- R-HSA-174411
- R-HSA-174430
- R-HSA-68952
- R-HSA-68962
- R-HSA-69091
- R-HSA-69166
- R-HSA-69183
- R-HSA-9710421
- End position
- 57646855
- Start position
- 57314805
- Chromosome
- 6
- Strand
- Forward
- Nucleoplasm
- Tissue specificity (tau)
- 0.852735
- Expression inequality (Gini)
- 0.427471
Expression in transcripts per million
- Cells - Cultured fibroblasts
- 27.34
- Cells - EBV-transformed lymphocytes
- 19
- Prostate
- 12.56
- Uterus
- 8.42
- Cervix - Ectocervix
- 7.27
Expression in transcripts per million
- Cells - Cultured fibroblasts27.34
- Cells - EBV-transformed lymphocytes19
- Prostate12.56
- Uterus8.42
- Cervix - Ectocervix7.27
- Cervix - Endocervix6.82
- Fallopian Tube6.74
- Bladder6.66
- Testis6.17
- Ovary6.05
- Colon - Sigmoid5.83
- Artery - Tibial5.74
- Vagina5.62
- Spleen5.47
- Skin - Sun Exposed (Lower leg)5.41
- Nerve - Tibial5.38
- Adipose - Subcutaneous5.17
- Artery - Aorta4.9
- Breast - Mammary Tissue4.85
- Skin - Not Sun Exposed (Suprapubic)4.74
- Colon - Transverse4.63
- Small Intestine - Terminal Ileum4.48
- Artery - Coronary4.41
- Esophagus - Muscularis4.36
- Thyroid4.28
And 29 more, listed on the interactive page.
- GO:0006269
- GO:0006270
- GO:0005654
- GO:0005658
- GO:0003899
- GO:0005515
- GO:0051539
- GO:0071667
Related records
Trials (4,736)
- (PGA) for Platinum-resistant/Refractory, Paclitaxel-Pretreated Recurrent Ovarian and Peritoneal Carcinoma
- (PM-01) IMPRIME PGG® With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer
- 1911GCCC: Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
- 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
- 2 Arm Study of Clofarabine IV in MDS Patients
- 2-Chlorodeoxyadenosine and Cytarabine in Patients With Idiopathic Hypereosinophilic Syndrome (HES)
- 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
- 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
- ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
- 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
- 24BRO681 : Alternating Gnp and mFOLFIRINOX for BR-PDAC
- 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen
- 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
- 3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
- 3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer
- 3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
- 3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer
- 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome
Drugs (7)
- Aspacytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Clofarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Cytarabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Fludarabine phosphate DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine DNA polymerase (alpha/delta/epsilon) inhibitor
- Gemcitabine hydrochloride DNA polymerase (alpha/delta/epsilon) inhibitor
- Troxacitabine DNA polymerase (alpha/delta/epsilon) inhibitor